Amsterdam Science Park’s Biotech company Ellogon.AI has received a KWF grant together with the Amsterdam UMC, Netherlands Cancer Institute and University of Amsterdam. The research project will focus on the selection of gastric and esophageal cancer (GEC) patients for immunotherapy.
With use of Artificial Intelligence, they will quantify well-known biomarkers and search for novel biomarkers which are characteristic for tumor-immune interactions, and analyse their spatial distribution and interdependance. In this way, new biomarker patterns can be identified that may predict successful immunotherapy treatment. The AI algorithms will be integrated in the clinical workflow during a pilot study and results will be correlated to immunotherapy response. An overview of the workflow of this project is shown in the figure.
Link to KWF grant (Dutch)
Looking for partners to collaborate. Or looking for a certain expertise? Or would you like to locate your business in the Amsterdam Science Park? Drop us a line and we help you to find a perfect match.
Subscribe to our newsletter and we will keep you updated on all that our park has to offer. It will arrive to your inbox five times a year and you can unsubscribe easily at any time.
Subscribe